

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**Form 8-K**

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (date of earliest event reported): October 9, 2014

**BioCorRx Inc.**

(Exact name of registrant as specified in  
its charter)

**333-153381**

(Commission File Number)

**Nevada**

(State or other jurisdiction  
of Incorporation)

**26-0685980**

(I.R.S. Employer  
Identification No.)

**601 N. Parkcenter Drive, Suite 103**

**Santa Ana, California 92705**

(Address of principal executive offices)

**(714) 462-4880**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01 Regulation FD Disclosure.**

On October 9, 2014, BioCorRx, Inc., a Nevada corporation (the “Company”), issued a press release announcing a shareholder conference call to be held on October, 16, 2014 at 11:00am Pacific Time, to discuss its financial results through June 30, 2014 and its operational outlook for the remainder of 2014 and 2015.

The information furnished pursuant to Item 7.01 (including Exhibit 99.1 hereto), shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01 Exhibits**

The following exhibits are furnished as part of this Form 8-K:

Exhibit 99.1	Press Release, dated October 9, 2014, issued by BioCorRx, Inc.
-----------------	--

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**BIOCORRX INC.**

Date: October 9, 2014

By: /s/ Lourdes Felix

Lourdes Felix  
Chief Financial Officer and Director

**BioCorRx, Inc. Announces Shareholder Conference Call**

BioCorRx, Inc. (BICX), a leader in addiction treatment, will host its first shareholder conference call on Thursday, October 16, 2014, at 11:00 am Pacific Standard Time to discuss its operations through the end of the second quarter 2014 and outlook for the remainder of this year and 2015. The call has been pushed back by one day since the original announcement was made. The conference call will include a Q&A session so that investors can have the opportunity to get their questions answered directly from the BioCorRx, Inc. management team. In order for an investor to have a better chance of receiving an answer to their question on the live call, the Company encourages shareholders to send their questions ahead of time to [investors@biocorr.com](mailto:investors@biocorr.com). Questions can also be sent during the call to the same email address, but the company has no way of predicting what the question volume will be during and immediately after the call. The call in number is 1-857-232-0157. Enter conference code 422095 when prompted by the system. A recording of the call will be released for those who can't attend. Simply go to <http://bicxcorp.com/get-updates/> to sign up for future company updates, including the recording of the conference call once it's made available.

**[Click here to view Recent National Television Media on the BioCorRx YouTube Channel](#)**

**[Click here for company Facebook page for more stories and media coverage](#)**

***About BioCorRx, Inc.***

BioCorRx, Inc. (OTCQB: BICX) is an addiction treatment and rehabilitation company on the leading edge of substance abuse addiction treatment. The company has developed a highly effective program called the Start Fresh Program™ consisting of two components used by various addiction clinics in the US. Clinic reports show that the treatment program has an extremely high success rate with individuals that complete the program. The first component of the program consists of an outpatient implant procedure performed by a licensed physician that delivers therapeutic levels of the drug Naltrexone, an opioid antagonist that significantly reduces physical cravings for alcohol and opioids, into the body. The second component of the program developed by BioCorRx, Inc. is a one on one coaching program specifically tailored for the treatment of alcoholism and other substance abuse addictions. For more information on BICX, visit [www.BioCorRx.com](http://www.BioCorRx.com)

***Safe Harbor Statement***

The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

Investor Relations  
SmallCapVoice.com, Inc.  
512-267-2430